术前肝功能障碍对左心室辅助装置患者结局的影响
该回顾性多中心队列纳入290例连续流左心室辅助装置(LVAD)植入患者,用MELD评分定义肝功能障碍,并以12.6为1年死亡率的最佳截断值分组。术前肝功能障碍者90天生存率为76%对91%(P=0.002),1年生存率为65%对90%(P<0.001),且栓塞事件与再次手术更多;1年随访时两组肝功能指标总体改善。
要点
- MELD>12.6的LVAD患者90天与1年生存率显著更低
- 术前肝功能障碍者栓塞事件及再次开胸探查更多
- 多数患者LVAD植入后1年内肝功能指标总体改善
核心结论
- 术前肝功能障碍与LVAD植入后更高的90天及1年死亡率相关。
- 尽管肝功能在两组均改善,仍需优化LVAD候选者选择标准。
研究设计与样本
- 回顾性多中心队列研究,纳入所有接受连续流LVAD植入的患者,共290例。
- 以MELD评分定义肝功能障碍,1年内收集超过40 000次肝功能指标测量。
主要发现
- 器械构成:78% HeartMate II、15% HVAD、7% HeartMate 3;平均年龄55(18)岁,76%为男性。
- ROC曲线分析确定MELD评分12.6为1年死亡率的最佳截断值。
- 90天生存率:肝功能障碍组76%,无肝功能障碍组91%(P=0.002)。
- 1年生存率:肝功能障碍组65%,无肝功能障碍组90%(P<0.001)。
- 术前肝功能障碍患者栓塞事件更多、再次手术探查更多。
关键数值与推荐
- MELD评分12.6为预测1年死亡率的最佳截断值,据此将队列二分为MELD<12.6与>12.6两组。
临床怎么用
- LVAD术前应评估MELD评分,评分>12.6提示早期与1年死亡风险更高。
- 对存活过第一年的患者,肝功能指标可望良好恢复,支持审慎优化候选者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated the impact of preoperative liver function on early and 1-year postoperative outcomes in patients supported with a left ventricular assist device (LVAD) and subsequent evolution of liver function markers. METHODS: A retrospective multicentre cohort study was conducted, including all patients undergoing continuous-flow LVAD implantation. The Model for End-stage Liver Disease (MELD) score was used to define liver dysfunction. RESULTS: Overall, 290 patients with an LVAD [78% HeartMate II, 15% HVAD and 7% HeartMate 3, mean age 55 (18), 76% men] were included. Over 40 000 measurements of liver function markers were collected over a 1-year period. A receiver operating characteristic curve analysis for the 1-year mortality rate identified the optimal cut-off value of 12.6 for the MELD score. Therefore, the cohort was dichotomized into patients with an MELD score of less than or greater than 12.6. The early (90-day) survival rates in patients with and without liver dysfunction were 76% and 91% (P = 0.002) and 65% and 90% at 1 year, respectively (P < 0.001). Furthermore, patients with preoperative liver dysfunction had more embolic events and more re-explorations. At the 1-year follow-up, liver function markers showed an overall improvement in the majority of patients, with or without pre-LVAD liver dysfunction. CONCLUSIONS: Preoperative liver dysfunction is associated with higher early 90-day and 1-year mortality rates after LVAD implantation. Furthermore, liver function improved in both patient groups. It has become imperative to optimize the selection criteria for possible LVAD candidates, since those who survive the first year show excellent recovery of their liver markers.
引用
- Yalcin YC, Muslem R, Veen KM, et al. Impact of preoperative liver dysfunction on outcomes in patients with left ventricular assist devices. Eur J Cardiothorac Surg. 2020. PMID: 31828334. doi:10.1093/ejcts/ezz337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。